Celltrion Submits South Korean IND for Subcutaneous Rheumatoid Arthritis Drug

MT Newswires Live

Jul 24

Celltrion (KRX:068270) has filed a Phase 3 IND application with the MFDS for CT-P13 SC (Zymfentra) in rheumatoid arthritis, aiming to demonstrate superiority over placebo at 12 weeks.

The 296-patient, 52-week trial seeks to expand the drug's approved uses beyond ulcerative colitis and Crohn's disease, leveraging its subcutaneous formulation for patient convenience, according to a bourse filing on Friday.

The company cautions that only about 10% of trial drugs ultimately gain marketing approval, and outcomes may not meet expectations.

This filing, confirmed on Friday, also supports commercial differentiation and regulatory trends favoring patient diversity, though investors should review all risk disclosures.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2653700516"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2653700516\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2653700516?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 16:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653700516","market":"us","top_or_hot":-1,"title":"Celltrion Submits South Korean IND for Subcutaneous Rheumatoid Arthritis Drug","media":"MT Newswires Live","content":"<html><body><p> Celltrion (KRX:068270) has filed a Phase 3 IND application with the MFDS for CT-P13 SC (Zymfentra) in rheumatoid arthritis, aiming to demonstrate superiority over placebo at 12 weeks.</p><p>The 296-patient, 52-week trial seeks to expand the drug's approved uses beyond ulcerative colitis and Crohn's disease, leveraging its subcutaneous formulation for patient convenience, according to a bourse filing on Friday.</p><p>The company cautions that only about 10% of trial drugs ultimately gain marketing approval, and outcomes may not meet expectations.</p><p>This filing, confirmed on Friday, also supports commercial differentiation and regulatory trends favoring patient diversity, though investors should review all risk disclosures.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Celltrion Submits South Korean IND for Subcutaneous Rheumatoid Arthritis Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCelltrion Submits South Korean IND for Subcutaneous Rheumatoid Arthritis Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-24 16:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Celltrion (KRX:068270) has filed a Phase 3 IND application with the MFDS for CT-P13 SC (Zymfentra) in rheumatoid arthritis, aiming to demonstrate superiority over placebo at 12 weeks.</p><p>The 296-patient, 52-week trial seeks to expand the drug's approved uses beyond ulcerative colitis and Crohn's disease, leveraging its subcutaneous formulation for patient convenience, according to a bourse filing on Friday.</p><p>The company cautions that only about 10% of trial drugs ultimately gain marketing approval, and outcomes may not meet expectations.</p><p>This filing, confirmed on Friday, also supports commercial differentiation and regulatory trends favoring patient diversity, though investors should review all risk disclosures.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IND","symbol_name":"Xtrackers Nifty 500 India ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2653700516","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653700516","pubTimestamp":1784882944,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Celltrion  has filed a Phase 3 IND application with the MFDS for CT-P13 SC  in rheumatoid arthritis, aiming to demonstrate superiority over placebo at 12 weeks.The 296-patient, 52-week trial seeks to expand the drug's approved uses beyond ulcerative colitis and Crohn's disease, leveraging its subcutaneous formulation for patient convenience, according to a bourse filing on Friday.The company cautions that only about 10% of trial drugs ultimately gain marketing approval, and outcomes may not meet expectations.This filing, confirmed on Friday, also supports commercial differentiation and regulatory trends favoring patient diversity, though investors should review all risk disclosures.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IND":"Xtrackers Nifty 500 India ETF"},"translate_title":"赛特瑞恩提交韩国皮下类风湿性关节炎药物IND","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IND":1.5},"content_text":"Celltrion (KRX:068270) has filed a Phase 3 IND application with the MFDS for CT-P13 SC (Zymfentra) in rheumatoid arthritis, aiming to demonstrate superiority over placebo at 12 weeks.The 296-patient, 52-week trial seeks to expand the drug's approved uses beyond ulcerative colitis and Crohn's disease, leveraging its subcutaneous formulation for patient convenience, according to a bourse filing on Friday.The company cautions that only about 10% of trial drugs ultimately gain marketing approval, and outcomes may not meet expectations.This filing, confirmed on Friday, also supports commercial differentiation and regulatory trends favoring patient diversity, though investors should review all risk disclosures.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}